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OBJECTIVE—Single nucleotide polymorphisms (SNPs) in in-
tron 1 of fat mass– and obesity-associated gene (FTO) are
strongly associated with human adiposity, whereas Fto
/ mice
are lean and Fto
/ mice are resistant to diet-induced obesity.
We aimed to determine whether FTO mutations are dispropor-
tionately represented in lean or obese humans and to use these
mutations to understand structure-function relationships within
FTO.
RESEARCH DESIGN AND METHODS—We sequenced all
coding exons of FTO in 1,433 severely obese and 1,433 lean
individuals. We studied the enzymatic activity of selected non-
synonymous variants.
RESULTS—We identiﬁed 33 heterozygous nonsynonymous vari-
ants in lean (2.3%) and 35 in obese (2.4%) individuals, with 8
mutations unique to the obese and 11 unique to the lean. Two
novel mutations replace absolutely conserved residues: R322Q in
the catalytic domain and R96H in the predicted substrate recog-
nition lid. R322Q was unable to catalyze the conversion of
2-oxoglutarate to succinate in the presence or absence of 3-meth-
ylthymidine. R96H retained some basal activity, which was not
enhanced by 3-methylthymidine. However, both were found in
lean and obese individuals.
CONCLUSIONS—Heterozygous, loss-of-function mutations in
FTO exist but are found in both lean and obese subjects.
Although intron 1 SNPs are unequivocally associated with obe-
sity in multiple populations and murine studies strongly suggest
that FTO has a role in energy balance, it appears that loss of one
functional copy of FTO in humans is compatible with being
either lean or obese. Functional analyses of FTO mutations have
given novel insights into structure-function relationships in this
enzyme. Diabetes 59:311–318, 2010
G
enome-wide association studies have revealed
that single nucleotide polymorphisms (SNPs)
within the ﬁrst intron of fat mass– and obesity-
associated gene (FTO) are strongly associated
with adiposity (1–4). These associations have been largely
consistent across multiple different ethnicities including
Europeans (5–8), Asians (9–11), Hispanics (12,13), and
Africans (13,14). At present, it remains unclear whether
these SNPs inﬂuence the expression or splicing of the FTO
gene and/or whether the unequivocal association with
obesity is causally related to alterations in expression or
function of FTO. If the effect of the intron 1 SNPs is
through FTO, it also remains unclear whether the obesity
risk SNPs result in a loss or a gain of FTO function. It
remains possible that the SNPs inﬂuence the expression
and/or function of neighboring genes and that such an
effect might underlie the association with adiposity. There
are several examples in metabolic disease where common
variants close to a particular gene are associated with
alterations in risk of common phenotypes such as fat mass
or risk of obesity, whereas rare loss- or gain-of-function
mutations in the same gene are associated with a more
severe version of the same metabolic phenotype (e.g.,
MCR4 [5,15–19], POMC [20,21], BDNF [22–24], and PCSK1
[25,26]). When information is available from both types of
variants, clarity of mechanistic understanding is greatly
enhanced. To establish whether nonsynonymous variants
of FTO might be enriched in either lean or obese subjects,
we sequenced the FTO coding region and intron-exon
boundaries in a large group of subjects with severe obesity
and a similarly sized group of individuals with lifelong
leanness. We have recently established that FTO encodes
a 2-oxoglutarate (2-OG) Fe
2-dependent dioxygenase (27).
In this study, we have examined the functional enzymatic
properties of naturally occurring variants to gain further
insights into structure-function relationships in the human
enzyme.
RESEARCH DESIGN AND METHODS
FTO was sequenced in 1,433 severely obese subjects. All adults had BMI 40
kg/m
2, and all obese children had a BMI 97th percentile for sex and age
(Table 1). Three hundred forty-ﬁve French morbidly obese adults were
recruited by the CNRS UMR8090 at Lille and the Department of Nutrition of
Paris Hotel Dieu Hospital. Thirty-three French morbidly obese adults were
patients of the CHRU Lille hospital. We also sequenced 287 Swiss morbidly
obese adults, all of them recruited after gastric surgery in Zurich, Switzerland.
Eighty-eight morbidly obese adult patients were recruited at the Antwerp
University Hospital. Three hundred ninety-nine French obese children were
recruited in CNRS UMR8090, and 281 obese children were recruited as part of
the Genetics of Obesity Study (GOOS) cohort (28). A total of 1,221 lean adult
subjects were part of the French DESIR (Data from an Epidemiological Study
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criteria were BMI 23 kg/m
2 at inclusion. We included 212 lean French
children selected from the Stanislas study (30). Inclusion criteria was BMI z
score (zBMI) 90th percentile for sex and age according to the Eastern
Cooperative Oncology Group (ECOG) (31). All patients were of European
ancestry. The study protocol was approved by all local ethics committees, and
informed consent was obtained from each subject before participating in the
study.
Genotyping of the FTO rs9939609 SNP. Genotyping of the FTO rs9939609
SNP was performed using a Taqman SNP Genotyping Assay (Applied Biosys-
tems) on an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems)
according to the manufacturer’s instructions.
Sequencing. We screened the nine exons of the FTO by direct nucleotide
sequencing. We ampliﬁed overlapping PCR fragments according to primers
and PCR-optimized conditions (available from the authors upon request). PCR
ampliﬁcations were inspected for single bands of expected sizes on agarose
gels before puriﬁcation with Agencourt AMPure on Biomek NX (Beckman
Coulter). Sequencing was achieved using the automated ABI Prism 3730xl
DNA Sequencer in combination with the Big Dye Terminator Cycle Sequenc-
ing Ready Reaction Kit 3.1 (Applied Biosystems), and puriﬁcation of sequenc-
ing reaction was performed with Agencourt CleanSEQ on Biomek NX
(Beckman Coulter). Sequences were assembled and analyzed with Se-
quencher software (GeneCodes).
Statistical analysis. The comparison of prevalence has been tested with
Fisher exact test, and the reported P values are two-sided. P values of 0.05
were considered to indicate statistical signiﬁcance.
Cloning of human FTO. Wild-type human FTO cDNA was ampliﬁed (Expand
DNA polymerase; Roche) using XhoI-tagged primers with the ﬁrst strand of
the reverse-transcribed cDNA (Superscript II; Invitrogen) from human brain
total RNA as a template. Using the XhoI sites, the resulting PCR product was
cloned into an NH2-terminal 6 His-tagged bacterial expression vector
(pET302/NT-His; Invitrogen). The FTO mutants were generated from cloned
wild-type FTO using the QuikChange Site-Directed Mutagenesis Kit (Strat-
agene) according to manufacturer’s protocols. The mutations were conﬁrmed
by DNA sequencing using Big Dye terminator chemistry (Applied Biosystems)
and electrophoresis on an ABI 3730 automated DNA sequencer. Sequences
were assembled and examined using Sequencher software (GeneCodes). All
primer sequences are available upon request.
Human wild-type and mutant FTO protein production. Human wild-type
and mutant FTO protein production was carried out as previously described
(32). Brieﬂy, expression plasmids were transformed into Escherichia coli
BL21-Gold (DE3; Stratagene) and cultured in 2 l Luria-Bertani broth and 50
g/ml carbenicillin to A600 1.0 at 37°C. Expression of the cloned gene was
induced by addition of 0.5 mmol/l isopropyl--D-1-thiogalactopyranoside
(IPTG) at 15°C for 4 h. The cells were harvested and washed in PBS, and
pellets were stored at 80°C. Cells were resuspended in 40 ml of lysis buffer
(50 mmol/l HEPES-KOH, pH 8, 2 mmol/l -mercaptoethanol, 5% glycerol, and
300 mmol/l NaCl), prior to addition of lysozyme (2 mg/ml). After 30 min of
incubation on ice, cells were sonicated and the lysate was clariﬁed by
centrifugation at 15000g for 20 min. The lysate was supplemented with
imidazole (10 mmol/l) and loaded onto a 1.5-ml Ni-NTA (nickel–nitrilotriacetic
acid)–agarose column (Qiagen) previously equilibrated in lysis buffer contain-
ing 10 mmol/l imidazole. The column was washed with 30 ml of lysis buffer
containing 10 mmol/l imidazole, followed by 7.5 ml of lysis buffer containing
40 mmol/l imidazole. The FTO protein was eluted in lysis buffer containing 250
mmol/l imidazole. The eluate was then loaded onto a 30-kDa concentrator
(Sartorius Stedium Biotech) and centrifuged at 2500g for 30 min. Then 2 ml of
buffer (20 mmol/l HEPES, pH 8, 5% glycerol, 50 mmol/l NaCl) was added to the
concentrated fraction, which was concentrated again down to 100 lb y
centrifugation at 2500g. FTO preparations were aliquoted and then stored at
80°C. FTO proteins were visualized by SDS–10% PAGE and stained with
Coomassie blue.
Assays of FTO activity. Conversion of
14C-2-oxoglutarate to
14C-succinate by
2-OG Fe
2-dependent DNA dioxygenases has been assayed previously (33).
This method was modiﬁed and optimized to assay FTO as previously
described (32). To measure the uncoupled reaction (no prime substrate
present), 1.5 mol/l FTO was assayed in 10 l reaction mixture containing
50 mmol/l HEPES-KOH, pH 7, 50 g/ml BSA, 4 mmol/l ascorbate, 75 mol/l
Fe(NH4)2(SO4)2, and 20 mol/l [5-
14C]-2-oxoglutarate (30 mCi/mmol from
Moravek Biochemicals) and incubated at 37°C for various times. To
measure stimulation of this activity by 3-methylthymidine, 1 mmol/l
3-methylthymidine (Moravek Biochemicals) was included in the assay mix.
The reaction was stopped by adding 5 l stop solution containing 20
mmol/l succinate, 20 mmol/l 2-OG, followed by 5 l 160 mmol/l dinitro-
phenylhydrazine, which precipitates 2-OG. This mix was incubated at room
temperature for 30 min. An additional 10 l 1 M 2-OG was added and incubated
for a further 30 min. The precipitate was removed by centrifugation. Clear
supernatant (10 l) was scintillation counted to monitor the
14C-succinate
generated.
RESULTS
Prevalence of nonsynonymous mutations in lean and
obese subjects. To identify potential loss-of-function
mutations, we screened the nine coding exons of FTO by
direct nucleotide sequencing in 1,433 extremely obese
subjects (753 adults with a BMI 40 kg/m
2 and 680
children with a BMI 97th percentile) and in 1,433 lean
subjects (1,221 adults with a BMI 23 kg/m
2 and 212
children recruited with a zBMI 90th percentile) accord-
ing to the ECOG (31), with an average zBMI close to the
50th percentile (zBMI  0.1 	 0.98) (Table 1). Addition-
ally, we also genotyped the FTO rs9939609 SNP (2) in all of
the patients. Genotype call rate was 99% in both lean and
obese subjects, and genotypic distribution obeyed the
Hardy-Weinberg equilibrium in the lean control subgroup
(P  0.58). We genotyped 363 duplicated DNA samples
and observed a concordance rate of 100%. In the lean
subgroup, genotype counts were 532 (TT), 668 (TA), and
224 (AA). In the obese subgroup, genotype counts were
367 (TT), 665 (TA), and 390 (AA). As expected, the obesity
risk A allele frequency was 11.6% higher in obese versus
lean subjects (obese: 50.8%; lean: 39.2%; OR 1.60 [1.44–
1.78]; P  1.2  10
18).
A total of 26 different rare (frequency 1% in the
present cohort) nonsynonymous variants were identi-
ﬁed in FTO (Table 2). The prevalence of nonsynony-
mous variants was similar between the two groups, with
33 lean (2.3%) and 35 obese (2.4%) individuals carrying
TABLE 1
Clinical characteristics for obese and lean subjects
n (male/female) Age (years) BMI (kg/m²) zBMI
Obese (adults: BMI 40 kg/m²;
children: BMI 97th percentile)
French adults 378 (79/299) 43.15 	 11.52 51.63 	 9.17 —
Swiss adults 287 (79/208) 41.56 	 11.21 52.32 	 5.80 —
Belgian adults 88 (36/52) 45.45 	 11.21 54.79 	 5.20 —
French children 399 (188/211) 10.56 	 3.23 — 5.01 	 1.04
English children 281 (135/146) 11.5 	 2.40 — 4.6 	 1.80
Lean (adults: BMI 23 kg/m²; children:
BMI 90th percentile)
French adults 1,221 (378/843) 43.26 	 9.37 20.42 	 1.28 —
French children 212 (96/116) 11.77 	 2.42 — 0.10 	 0.98
Data are means 	 SD unless otherwise indicated.
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were observed between children and adults (Table 2).
We found that a subset of those was unique to each
group. Eight (A134T, G187A, M223V, A241T, H419R,
E471G, I492V, and V493F) nonsynonymous mutations
were identiﬁed uniquely in the obese cohort, whereas 11
(P5L, E24K, R80P, P93R, V94I, N143S, I148R, D189N,
E234D, R316Q, and P399H) were identiﬁed uniquely in
the lean cohort (Table 3). G187A (n  2), A241T (n  2),
and V493F (n  4) were identiﬁed in multiple obese
subjects (Table 3). Seven variants (R96H, L146M, A163T,
V201I, S256N, R322Q, and A405V) were present in both
cohorts. The prevalence of synonymous mutations was
not signiﬁcantly different in obese compared with lean
subjects (0.8% vs. 0.4%, P  0.05; Table 4). All mutations
were identiﬁed in heterozygous form, and no nonsense
variants were reported in the studied populations. Thus,
there is no obvious enrichment of nonsynonymous
mutations in lean or obese individuals.
Functional properties of nonsynonymous mutations.
FTO is a member of the AlkB homologue (ABH) protein
family, which numbers nine homologues in humans (27).
Most 2-OG and Fe
2-dependent dioxygenases slowly cat-
alyze the conversion of 2-OG to succinate even in the
absence of their prime substrate (33), and this so-called
uncoupled reaction may be stimulated by substrates or
their analogues. We have previously reported that murine
Fto is capable of demethylating the base 3-methylthymine
in the context of single-stranded DNA (27), but that
reaction proceeds rather slowly. Human FTO can also
accomplish this reaction, but again at a very slow
turnover rate (34). We have previously exploited the
ability of wild-type human FTO to efﬁciently catalyze
the conversion of 2-OG to succinate in a manner that is
TABLE 2
Summary of all nonsynonymous mutations found in obese and lean subjects
Nonsynonymous mutations
Obese
children
Obese
adults
All obese
subjects
Lean
children
Lean
adults
All lean
subjects
P5L 1 1
E24K 1 1
R80P 1 1
P93R 1 1
V94I 1 1
R96H 1 1 1 1
A134T 1 1
N143S 1 1
L146M 1 1 2 123
I148R 1 1
A163T 2 5 7 145
G187A 2 2
D189N 1 1
V201I 2 2 112
M223V 1 1
E234D 1 1
A241T 2 2
S256N 3 5 8 369
R316Q 1 1
R322Q 1 1 1 1
P399H 1 1
A405V 1 1 1 1
H419R 1 1
E471G 1 1
I492V 1 1
V493F 1 3 4
Prevalence of mutation
carriers (%) 1.32 3.45 2.44 3.77 2.05 2.31
Data in boldface indicate combined adult and children numbers.
TABLE 3
Summary of nonsynonymous mutations unique to the lean or the
obese group
Nonsynonymous mutations n
Obese subjects
A134T 1
G187A 2
M223V 1
A241T 2
H419R 1
E471G 1
I492V 1
V493F 4
Prevalence of mutations (%) 0.91
Lean subjects
P5L 1
E24K 1
R80P 1
P93R 1
V94I 1
N143S 1
I148R 1
D189N 1
E234D 1
R316Q 1
P399H 1
Prevalence of mutations (%) 0.77
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3-methylthymidine (32), and have used this assay
throughout this study.
Analysis based on a three-dimensional (3D) homology
model (27) comparing FTO with the known 3D structure
of three members of the family (ABH2, ABH3, and AlkB)
(35) suggests that FTO can be divided in several structural
and functional regions (Fig. 1). The more conserved
NH2-terminal segment contains 1) a putative nuclear lo-
calization signal present only in FTO (36), 2) a double-
stranded -helix in a “jellyroll fold” containing all the
catalytic apparatus that is well conserved in all ABHs, 3)a
substrate recognition lid that is very different in each ABH
member but phylogenetically well conserved among spe-
cies within each paralog, and 4) two long insertions,
absent in other ABH members, that are of variable lengths
in different species and are substantially less conserved
than the rest of the protein. The COOH-terminal domain,
whose structure and function remain unknown, is absent
in all other ABH members but contains several residues
that are absolutely conserved among highly diverse
species.
Two of the naturally occurring mutations that we de-
tected, namely R316Q (found in one lean subject) and
R322Q (found in one lean and one obese), replace abso-
lutely conserved residues in the catalytic domain (Fig. 2).
The model predicts R316 and R322 to be involved in 2-OG
coordination, by forming stabilizing salt bridges with the
carboxylates of this cosubstrate. We have previously stud-
ied the enzymatic property of R316Q (32), and in this study
we have examined R322Q compared with wild-type FTO
(Fig. 3A). As predicted, R322Q, like R316Q (32), was
completely unable to convert 2-OG to succinate in either
the absence or presence of 3-methylthymidine.
One mutation, R96H (detected in one lean and one
obese subject) occurs at an absolutely conserved residue
within the putative “substrate recognition lid” of the
TABLE 4
Summary of all synonymous mutations found in lean and obese
subjects
Synonymous mutations Obese subjects (n) Lean subjects (n)
T6T 5 1
P33P 2 —
L44L 1 —
P93P 1 —
A174A 1 —
E217E 1 —
I334I — 1
Q336Q — 1
V374V 1 —
C456C — 1
L464L — 1
I492I — 1
Prevalence of
mutations (%) 0.84 0.42
substrate recognition lid
putative nuclear localization 
signal (NLS)
COOH-terminal domain of  
unknown function
catalytic machinery
surface loops of variable length and composition
strictly conserved 2-OG and Fe binding residues
        10         20         30         40         50         60
MKRTPTAEER EREAKKLRLL EELEDTWLPY LTPKDDEFYQ QWQLKYPKLI LREASSVSEE
        70         80         90        100        110        120
LHKEVQEAFL TLHKHGCLFR DLVRIQGKDL LTPVSRILIG NPGCTYKYLN TRLFTVPWPV
       130        140        150        160        170        180
KGSNIKHTEA EIAAACETFL KLNDYLQIET IQALEELAAK EKANEDAVPL CMSADFPRVG
       190        200        210        220        230        240
MGSSYNGQDE VDIKSRAAYN VTLLNFMDPQ KMPYLKEEPY FGMGKMAVSW HHDENLVDRS
       250        260        270        280        290        300
AVAVYSYSCE GPEEESEDDS HLEGRDPDIW HVGFKISWDI ETPGLAIPLH QGDCYFMLDD
310        320        330        340        350        360
LNATHQHCVL AGSQPRFSST HRVAECSTGT LDYILQRCQL ALQNVCDDVD NDDVSLKSFE
       370        380        390        400        410        420
PAVLKQGEEI HNEVEFEWLR QFWFQGNRYR KCTDWWCQPM AQLEALWKKM EGVTNAVLHE
       430        440        450        460        470        480
VKREGLPVEQ RNEILTAILA SLTARQNLRR EWHARCQSRI ARTLPADQKP ECRPYWEKDD
       490        500
ASMPLPFDLT DIVSELRGQL LEAKP
FIG. 1. Predicted structural and functional regions of FTO based on a 3D homology model of FTO (27).
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region of the molecule is known to be required for binding
of the primary substrate but is not involved in interactions
with the cosubstrate 2-OG. Notably, in contrast to R322Q,
R96H retained some ability to convert 2-OG to succinate,
but this activity was not enhanced by the presence of
3-methylthymidine (Fig. 3B), a ﬁnding consistent with the
hypothesis that R96 functions as part of the primary
substrate recognition lid.
We also tested the enzymatic activity of several other
variants representing the different regions of FTO (P5L,
V94I, I148R, M223V, E234D, A241T, A405V, I492V, and
V493F) (Fig. 2). None of these variants, all of which are
located in less conserved positions, had any signiﬁcant
impact on enzymatic activity (Fig. 3C and D and data not
shown).
We have previously demonstrated that murine Fto local-
izes to the nucleus (27). Bioinformatic analysis suggests
that a sequence of 18 amino acid residues in the NH2-
terminal of FTO encodes a putative nuclear localization
signal (Fig. 1). P5L affects a residue within this putative
nuclear localization domain. COS-7 cells were transfected
with a construct expressing WT FTO-GFP (wild-type FTO
green ﬂuorescent protein), P5L FTO-GFP mutant protein,
or GFP alone (mock-GFP). WT FTO-GFP and P5L FTO-
GFP colocalized with DAP1, whereas GFP alone was seen
in both the cytoplasm and the nucleus (supplementary Fig.
1, available in an online appendix at http://diabetes.
Mutants assayed: highlighted in red or blue
Red = inactive
Blue = active
Lean subjects
Obese subjects
P5L(1)
V94I(1)
R96H(1)
I148R(1)
E234D(1)
R316Q(1) P399H(1)
M223V(1)
A241T(2) A405V(1)
I492V(1)
A163T(7)
L146M(2) 
S256N(8)
A163T(5)
S256N(9)
L146M(3)
E24K(1) R80P(1)
P93R(1)
A134T(1) 
N143S(1) 
G187A(2)
D189N(1)
V201I(2)
V201I(2)
R322Q(1)
R322Q(1)
A405V(1)
E471G(1) 
V493F(4) H419R(1)
R96H(1)   
Catalytic domain
Putative nuclear localization signal (NLS)
COOH-terminal domain of unknown function
FIG. 2. Distribution of nonsynonymous mutations along FTO exons and functional domains. Highlighted mutants are those that have been assayed
in the uncoupled reaction in the absence and presence of 3-methylthymidine. Mutants that were inactive in the uncoupled reaction assay with
3-methylthymidine are shown in red, whereas those that did not affect this reaction are shown in blue.
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P5L does not appear to impair the nuclear localization of the
protein.
DISCUSSION
Recent genome-wide association efforts have been highly
successful in identifying a large number of common ge-
netic variants reliably associated with important human
diseases and quantitative traits (2,32,37). Understanding
the precise biological mechanisms underlying such asso-
ciations will provide a major scientiﬁc challenge that will
require a multiplicity of approaches in humans and in
model organisms. FTO exempliﬁes many of these chal-
lenges. Although SNPs in intron 1 of FTO are unequivo-
cally associated with adiposity in multiple populations,
there is still no evidence that those SNPs inﬂuence the
expression or splicing of FTO itself. FTO is located
adjacent to other genes, the expression or function of
which could conceivably inﬂuence energy balance
(10,36,38). Recent ﬁndings in mice rendered null for Fto
support the notion that Fto itself has an important inﬂu-
ence on energy balance. Fto-null mice are small, are lean,
have an increased metabolic rate, and are hyperphagic,
whereas Fto
/ mice are resistant to diet-induced obesity
(39). Given that information, it is reasonable to speculate
that loss-of-function mutations in FTO might be more
common in lean rather than obese humans. To test this
hypothesis, we sequenced FTO in a large number of lean
and obese subjects and found that 1) nonsynonymous
mutations were equally common in both the obese and
lean cohorts and 2) heterozygous mutations that severely
impaired enzymatic activity of FTO were found in both
lean and obese individuals with no other obvious major
clinical phenotypes. Our ﬁndings illustrate the importance,
when sequencing “candidate” genes whose candidacy de-
rives largely from genome-wide association studies in
extreme phenotypes, of studying both ends of the spec-
trum of a quantitative trait. (If we had considered FTO to
be an “obesity gene” and sequenced only obese subjects,
the ﬁnding of loss-of-function mutations would have been
misleading.) From our human genetic data, we can con-
clude that heterozygosity for a severely dysfunctional FTO
allele is compatible with being either lean or obese in
humans. Understanding the relationship between SNPs in
intron 1 of FTO with human adiposity will require other
approaches. In collaboration with Dr. Laurence Colleaux
from Hopital Necker Paris and others, we have recently
found a consanguineous Israeli-Arab family in which nine
siblings were homozygous for the R316Q mutation in FTO
(32). All homozygous carriers were severely growth re-
tarded, had multiple congenital malformations, and died in
infancy. Although heterozygous parents of these children
had no obvious metabolic phenotype, ongoing efforts are
directed at establishing measures of adiposity in heterozy-
gous versus wild-type relatives (32).
Our studies have brought new insights into aspects of
the structure-function relationship of the human FTO
enzyme. Human FTO can catalyze the uncoupled reaction
(2-OG to succinate) and is stimulated by 3-methylthymi-
dine (32), and we have used this as a robust test of FTO’s
catalytic activity. As predicted, we found that the arginine
at position 322 is essential for the catalytic activity of
human FTO, and we have made similar observations for
R316Q (32). Mutation of the arginine corresponding to
human 316 in mouse Fto (R313A) also generated an
inactive enzyme (27). Perhaps more interestingly, we have
demonstrated that mutation of R96 to histidine in human
FTO produces an enzyme that is capable of some basal
conversion of 2-OG to succinate but is insensitive to the
effects of 3-methylthymidine. These ﬁndings are consistent
with R96 being part of the so-called substrate recognition
lid that is responsible for substrate ﬁxation and selectivity.
Thus, the lid is well conserved among species orthologues,
but has diverged substantially in the various paralogs of
ABH to accommodate different substrates. For instance,
R131 at this position in the lid of ABH3 is positioned to
interact with 1-meA N3, and R131A in ABH3 abolishes the
activity toward 1-me-A containing single-stranded DNA
(27).
Although all of the other nonsynonymous variants we
tested appeared to have normal enzymatic activity, we
should express caution about categorically stating that
these are fully wild type in function. First, we do not know
what the true natural primary substrate(s) of FTO is (are),
and it is entirely possible that mutations that affect FTO’s
actions on this elusive substrate will not necessarily
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FIG. 3. Activity of wild-type (WT) and mutant FTO proteins. Decar-
boxylation of
14C-2-oxoglutarate to
14C-succinate by 1.5 mol/l FTO in
the absence or presence of 3-methylthymidine was measured at various
time intervals. A: WT1 and R322Q FTO proteins. B: WT1 and R96H FTO
proteins. C: WT2, P5L, V94I, and A241T FTO proteins. D: WT3 and
V493F FTO proteins. WT1, 2, and 3 are three different wild-type FTO
preparations made at the same time as the mutant proteins with which
they are assayed in A, B, C,o rD. Open symbols indicate without
3-methylthymidine; closed symbols indicate with 1 mmol/l 3-methylthy-
midine (also indicated by  and ). E: SDS–10% PAGE of FTO protein
preparations stained with Coomassie blue. Per lane, 3 g total protein
was loaded. FTO and size markers are indicated.
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demonstrated that FTO, in vitro, possesses dioxygenase
activity, whether it has any other biological role, enzy-
matic or otherwise, is yet to be determined. This could
potentially be of relevance to V493F, a COOH-terminal
mutation that was found only in the obese population but
was found in four different individuals (Fig. 2), and yet did
not impact on the ability of FTO to convert 2-OG to
succinate or its stimulation by 3-methylthymidine (Fig.
3D). The COOH-terminal region of FTO, although highly
conserved across species, is not shared with other mem-
bers of the ABH family, and its structure and function are
unknown.
We noted two potentially interesting observations re-
garding the COOH-terminal region of the protein. First, on
a “mutations per nucleotide” basis, nonsynonymous muta-
tions are found 
3 times less frequently in the COOH-
terminus than in the rest of the molecule. Second,
although nonsynonymous variants elsewhere in the mole-
cule are found equally in obese and lean subjects, eight
such variants found in the COOH-terminus were detected
in obese subjects and only two in lean (Fig. 2). These
preliminary observations are of potential interest and
might lead to a better understanding of FTO function and
its role in energy homeostasis localization.
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